Cell and Gene Therapy
CGT Reagents for Next-Generation Therapies
Krishgen Biosystems is your trusted partner for high-quality Cell & Gene Therapy (CGT) reagents in India, supporting researchers and biopharmaceutical companies in the development of next-generation therapies.
From Starting Material to GMP
Cell and gene therapy development isn't one path — select your track below. Our portfolio across several partners supports every stage, matched to the reagents and methods each pathway actually uses.
Represented Brands
Vector-based in vivo or ex vivo gene delivery — engineering a transgene construct and packaging it into a viral vector for delivery.
Choose Vector System & Starting Material
Producer cell lines (e.g. HEK293), plasmid backbones, media and reagents for generation and maintenance.
Engineer the Transgene Construct
CRISPR/Cas9 tools and mRNA, miRNA, siRNA reagents for precise genome and gene-expression editing, plasmid design.
Produce & Purify Viral Vector
Transfection reagents, AAV and lentivirus production kits, gene delivery systems matched to your vector strategy.
Scale to GMP
GMP-grade reagents and media/supplements as programs progress toward clinical-grade production.
Autologous or allogeneic T-cell engineering — sourcing patient/donor T cells and installing a CAR construct via viral transduction or non-viral editing.
Source & Activate T Cells
Leukapheresis-derived T cells, activation reagents and beads for initial expansion setup.
Engineer with CAR Construct
Viral transduction (lentiviral/retroviral) or non-viral CRISPR knock-in — both the engineering and the delivery event.
Expand & Formulate
Cell expansion media and reagents, formulation reagents for infusion-ready product.
Scale to GMP & Release Testing
GMP-grade reagents plus potency and release testing ahead of clinical use.
NK-cell engineering — distinct sourcing and delivery mechanism from CAR-T, typically using non-viral methods due to NK resistance to viral transduction.
Represented Brands
Source NK Cells
Donor peripheral blood NK cells or iPSC-derived NK cell lines, media and reagents for maintenance.
Engineer with CAR Construct
Typically mRNA electroporation rather than viral transduction — NK cells resist standard viral delivery methods.
Expand & Formulate
NK-cell expansion media and reagents, formulation for infusion-ready product.
Scale to GMP
GMP-grade reagents and media/supplements as programs progress toward clinical-grade production.
iPSC and MSC-based workflows — often involve no genetic editing at all. Differentiation to a target lineage is the step this pathway needs that others don't.
Represented Brands
Source & Reprogram / Isolate
Fibroblast/PBMC reprogramming to iPSC, or direct MSC isolation from tissue.
Maintain & Expand
Pluripotency maintenance media, feeder-free culture reagents. Genetic editing is optional here, not universal.
Differentiate to Target Lineage
Differentiation media and growth factors driving cells toward the intended target cell type.
Scale to GMP Banking
GMP-grade reagents for cell banking as programs move toward clinical-grade production.
Browse by Category
Built around real workflows, not a catalog listing
Exclusive partnerships with leading global suppliers.
RUO and GMP-grade reagents to support research and clinical development.
Technical expertise and support for CGT workflows.
Rapid delivery across India.